EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieOpen Access

Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague

Rindra Vatosoa Randremanana, Mihaja Raberahona, Josephine Bourner iD, Minoarisoa Rajerison, Tansy Edwards, Ravaka Randriamparany, Tsinjo Fehizoro Razafindratsinana, Lisy Hanitra Razananaivo, Gabriella Zadonirina, Théodora Mayouya-Gamana, Alex Paddy Abdel Salam, Reziky Tiandraza Mangahasimbola und 7 weitere

New England Journal of Medicine · 07.08.2025 · 393 (6) · 544-555

DOI: 10.1056/nejmoa2413772 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 07.08.2025. Verfasst von Rindra Vatosoa Randremanana und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur de Madagascar, Antananarivo. Hauptthemen laut MEDLINE: Aminoglycosides, Anti-Bacterial Agents, Ciprofloxacin, Plague. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Foreign, Commonwealth and Development Office, Wellcome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminoglycosidesAnti-Bacterial AgentsCiprofloxacinPlagueAdolescentAdultChildFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralDrug CombinationsDrug Therapy, CombinationMadagascarTreatment FailureYersinia pestisChild, PreschoolAgedInjections, IntramuscularStreptomycinGentamicinsInfusions, Intravenous

Substanzen

AminoglycosidesAnti-Bacterial AgentsCiprofloxacinDrug CombinationsStreptomycinGentamicins

Autor:innen und Institutionen

  • Institut Pasteur de Madagascar, Antananarivo.
  • Centre Hospitalier Universitaire (CHU) Joseph Raseta Befelatanana, Antananarivo, Madagascar.
  • Équipe de Recherche Clinique en Maladies Infectieuses, Antananarivo, Madagascar.
  • Centre d'Infectiologie Charles Mérieux, Université d'Antananarivo, Antananarivo, Madagascar.
  • International Severe Acute Respiratory and Emerging Infection Consortium, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London.

ORCID-Profile: Josephine Bourner

Förderung

  • Wellcome Trust
  • Foreign, Commonwealth and Development Office
  • Wellcome

Zitieren

APA

Randremanana, R. V., Raberahona, M., Bourner, J., Rajerison, M., Edwards, T., Randriamparany, R., Fehizoro Razafindratsinana, T., Razananaivo, L. H., Zadonirina, G., Mayouya-Gamana, T., Salam, A. P. A., Mangahasimbola, R. T., Andrianaivoarimanana, V., Pesonel, E., Rakotoarivelo, R. A., Randria, M. J. D., Horby, P., Olliaro, P., & IMASOY Study Group (2025). Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague. New England Journal of Medicine, 393(6), 544-555. https://doi.org/10.1056/nejmoa2413772

Vancouver

Randremanana RV, Raberahona M, Bourner J, Rajerison M, Edwards T, Randriamparany R, et al. Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague. New England Journal of Medicine. 2025;393(6):544-555. doi:10.1056/nejmoa2413772

BibTeX
@article{Randremanana2025,
  author = {Randremanana, Rindra Vatosoa and Raberahona, Mihaja and Bourner, Josephine and Rajerison, Minoarisoa and Edwards, Tansy and Randriamparany, Ravaka and Fehizoro Razafindratsinana, Tsinjo and Razananaivo, Lisy Hanitra and Zadonirina, Gabriella and Mayouya-Gamana, Théodora and Salam, Alex Paddy Abdel and Mangahasimbola, Reziky Tiandraza and Andrianaivoarimanana, Voahangy and Pesonel, Elise and Rakotoarivelo, Rivonirina Andry and Randria, Mamy Jean de Dieu and Horby, Peter and Olliaro, Piero and IMASOY Study Group, IMASOY Study Group},
  title = {Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {6},
  pages = {544--555},
  doi = {10.1056/nejmoa2413772}
}
Kostenlos starten →